What role, if any, should AI play in developing biotech and pharma manuscripts?
Svetlana Pidasheva, PhD, is the Director of Scientific Communications at Radius Health, with 19 years in biotech and pharma across multiple therapeutic areas and company stages, and a PhD in experimental medicine from McGill University.
In this episode, Dr. Pidasheva joins Kristen to discuss the rigorous, human-led process behind developing a scientific manuscript—and whether AI can fit into that process.
Note: Dr. Pidasheva shares a quick disclaimer that all opinions are her own and not those of her employer, Radius Health.
Dr. Pidasheva explains that when she first moved into scientific communications, she assumed industry manuscripts would follow an academic pattern: do the research, write the paper, send it to a supervisor, and submit. She quickly learned that in pharma, manuscript development is less about drafting text and more about orchestrating a disciplined process—one that involves understanding compliance, adhering to publication standards, and collaborating with physicians who conducted the trials and understand what matters clinically.
She walks through how teams convene advisory-style publication committee meetings to digest data, hear insights from physicians, refine strategy, and make careful decisions about messaging, figures, authorship, and presentation. This human-led process is integral to the credibility of the final publication and should not be replaced with AI-driven automation.
Expertly Said is a podcast on the art and impact of communication. Each episode features a conversation about how people connect with understand and influence one another.
Hit subscribe wherever you get your podcasts, and follow along as we bring great ideas to the world, one conversation at a time.
We use cookies to improve your experience on our site. To find out more, read our privacy policy and terms and conditions.
